drugset / Trial / NCT07151716

Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients

NCT07151716

Phase 4 Completed 100 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Patients in the intensive care unit (ICU) often develop anxiety and agitation, sleep disturbances, and delirium. Delirium occurrence is associated with worse early and long-term outcomes. Dexmedetomidine and ketamine are recommended for sedation and analgesia in postoperative ICU patients, but each may induce side effects. The sedative effects of dexmedetomidine can help mitigate the neuropsychiatric side effects of esketamine. Recent studies showed that dexmedetomidine-esketamine combination improved analgesia and sleep quality without increasing side effects. This trial is designed to test the hypothesis that dexmedetomidine-esketamine combination for sedation and analgesia in postoperative ICU patients may reduce delirium.

Timeline

Start
2025-10-21
Primary completion
2026-03-31
Completion
2026-04-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified
Subject Esketamine Other / unclassified

Indications